The Journal of Experimental Medicine
Torrey Pines Biolabs
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online
doi:10.1084/jem.20082299
The Journal of Experimental Medicine, Vol. 206, No. 4, 833-847
The Rockefeller University Press, 0022-1007 $30.00
© Delloye-Bourgeois et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 7311K)
Right arrow PDF+supp data (10960K)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delloye-Bourgeois, C.
Right arrow Articles by Mehlen, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delloye-Bourgeois, C.
Right arrow Articles by Mehlen, P.
Related Collections
Right arrowRelated Article
Right arrowRelated In this Issue article
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

ARTICLE

Netrin-1 acts as a survival factor for aggressive neuroblastoma

Céline Delloye-Bourgeois1, Julien Fitamant1, Andrea Paradisi1, David Cappellen2, Setha Douc-Rasy2, Marie-Anne Raquin3, Dwayne Stupack4, Akira Nakagawara5, Raphaël Rousseau6, Valérie Combaret6, Alain Puisieux6, Dominique Valteau-Couanet3, Jean Bénard2, Agnès Bernet1, and Patrick Mehlen1

1 Apoptosis, Cancer and Development Laboratory, Equipe labellisée ‘La Ligue’, Centre National de la Recherche Scientifique UMR5238, Université de Lyon, 69008 Lyon, France
2 Molecular Interactions and Cancer Centre, National de la Recherche Scientifique UMR 8126 and IFR54, and 3 Oncopediatric Department, Gustave Roussy Institute, 94805 Villejuif Cedex, France
4 Department of Pathology, School of Medicine, Moores Cancer Center, University of California, San Diego, La Jolla, CA 92093
5 Division of Biochemistry, Chiba Cancer Center Research Institute, Chiba 260-8717, Japan
6 Institut National de la Santé et de la Recherche Médicale U590, Unité d'Oncologie Moléculaire, Université de Lyon, 69008 Lyon, France

CORRESPONDENCE Patrick Mehlen: mehlen{at}lyon.fnclcc.fr

Neuroblastoma (NB), the most frequent solid tumor of early childhood, is diagnosed as a disseminated disease in >60% of cases, and several lines of evidence support the resistance to apoptosis as a prerequisite for NB progression. We show that autocrine production of netrin-1, a multifunctional laminin-related molecule, conveys a selective advantage in tumor growth and dissemination in aggressive NB, as it blocks the proapoptotic activity of the UNC5H netrin-1 dependence receptors. We show that such netrin-1 up-regulation is a potential marker for poor prognosis in stage 4S and, more generally, in NB stage 4 diagnosed infants. Moreover, we propose that interference with the netrin-1 autocrine loop in malignant neuroblasts could represent an alternative therapeutic strategy, as disruption of this loop triggers in vitro NB cell death and inhibits NB metastasis in avian and mouse models.


J. Bénard, A. Bernet, and P. Mehlen contributed equally to this paper.

Abbreviations used: CAM, chorioallantoic membrane; DAPK, DAP kinase; DCC, deleted in colorectal cancer; MNA, MYCN amplification; mRNA, messenger RNA; Myoc, myocardium; NB, neuroblastoma; PTX, primary tumor xenograft; Q-RT-PCR, quantitative RT-PCR; siRNA, small interfering RNA; TUNEL, terminal deoxynucleotidyl transferase–mediated dUTP-biotin nick end labeling.

© 2009 Delloye-Bourgeois et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Article

Save yourself, cancer cell
Mitch Leslie
J. Exp. Med. 2009 206: 726-727. [Full Text] [PDF]

Related In this Issue article

Save yourself, cancer cell
Mitch Leslie
J. Exp. Med. 2009 206: 726-727. [Full Text] [PDF]



This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS